Table 1. Observation, test and evaluation schedule canagliflozin treatment group.

Visit	Observation period
	Before starting	Week 0	Week 12 (month 3)	Week 24 (month 6)	Week 52 (month 12)
Schedule window	–	–	±6 week	±9 week	±12 week
Informed consent	X
Enrolment	X
Allocation	X
Patient characteristics	X
Physical examination	X	X	X	X	X
Blood test		X	X	X	X
Plasma BNP		X	X	X	X
Image tests*		X		X	X
Kt/Vurea, PET†		X		X	X
Use of concomitant drugs
Adverse events

^*Image tests; CT scan, cardiac echo, cervical echo, Holter ECG, chest X-ray and bone mineral density measurement at week 0 should be performed 12 weeks prior to the start of administration to week 0.

^†Kt/Vurea, PET; week 0 should be performed 24 weeks prior to the start of administration to 0 week. Week 24 is not required.

BNPbrain natriuretic peptidePETperitoneal equilibration test